Physician profile
Michael L Levine
NPI 1427152081
$5,803.44
in general payments reported to CMS, 2019-2025
31 companies · $815 in 2025
The $815 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $654 · 2021: $731 · 2022: $875 · 2023: $662 · 2024: $839 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.92 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,070.40 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Abbvie INC. | $706.55 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $622.56 | 2019-2024 | Tecnis Simplicity, Veritas Vision System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $385.71 | 2019-2021 | |
| Allergan, INC. | $377.48 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $260.13 | 2022-2024 | Omidria, Rayone Spheric, Rayone Aspheric |
| Kala Pharmaceuticals, INC. | $255.23 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $225.21 | 2019-2023 | Cequa |
| Bausch & Lomb Americas INC. | $221.63 | 2023-2025 | Stellaris, Vyzulta, Miebo |
| Mallinckrodt Hospital Products INC. | $191.80 | 2021-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $190.82 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $172.38 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $170.67 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $153.84 | 2019-2022 | |
| Oyster Point Pharma, INC. | $137.76 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $97.82 | 2021-2022 | |
| Horizon Therapeutics Plc | $70.19 | 2021-2022 | |
| Amgen INC. | $69.08 | 2024-2025 | Tepezza |
| Rxsight INC | $62.97 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Ani Pharmaceuticals, INC. | $49.26 | 2025 | Purified Cortrophin Gel |
| Sight Sciences, INC. | $46.23 | 2019-2021 | |
| Dompe US, INC. | $40.38 | 2021-2022 | |
| Beaver-Visitec International, INC. | $36.00 | 2021 | |
| Eyepoint US, INC. | $31.26 | 2019 | |
| Glaukos Corporation | $29.53 | 2025 | Idosetr |
| Astellas Pharma US INC | $29.12 | 2024 | Izervay |
| Harrow Eye, LLC | $23.20 | 2025 | Vevye |
| Lensar, INC. | $21.52 | 2024 | Lensar Laser System |
| Lombart Brothers, INC. | $21.03 | 2024 | Opd-III |
| Regeneron Healthcare Solutions, INC. | $19.69 | 2019 | |
| Omeros Corporation | $13.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.